跳至主要内容
临床试验/NCT02335489
NCT02335489终止不适用

A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Neuropathic Pain of the Foot and/or Lower Leg

Abbott Medical Devices1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2013年3月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
10
试验地点
1
主要终点
Change in Pain Intensity for Overall Pain From Pre-treatment Baseline

研究概览

简要总结

14-SMI-2013 is a post market, observational, questionnaire based study to assess the effectiveness of the commercially available Axium neurostimulator in the management of neuropathic pain of the foot and/or lower limb

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is at least 18 years old
  • Subject is able and willing to comply with the follow-up schedule and protocol
  • Chronic, intractable pain in the foot and/or lower leg for at least 6 months
  • Failed conservative treatments for chronic pain including but not limited to pharmacological therapy, physical therapy and interventional pain procedures for chronic pain
  • Minimum baseline pain rating of 60 mm on the Visual Analog Scale in the primary region of pain
  • Subject is able to provide written informed consent

排除标准

  • Female subject of childbearing potential is pregnant/nursing, plans to become pregnant or is unwilling to use approved birth control
  • Escalating or changing pain condition within the past month as evidenced by investigator examination
  • Subject has had corticosteroid therapy at an intended site of stimulation within the past 30 days
  • Subject has had radiofrequency treatment of an intended target Dorsal Root Ganglion within the past 3 months
  • Subject currently has an active implantable device including implantable cardioverter defibrillator, pacemaker, spinal cord stimulator or intrathecal drug pump
  • Subject is unable to operate the device
  • Subjects with indwelling devices that may pose an increased risk of infection
  • Subjects currently has an active infection
  • Subject has participated in another clinical investigation within 30 days
  • Subject has a coagulation disorder or uses anticoagulants that, in the opinion of the investigator, precludes participation
  • Subject has been diagnosed with cancer in the past 2 years.

结局指标

主要结局

Change in Pain Intensity for Overall Pain From Pre-treatment Baseline

时间窗: Baseline, 3, 6 and12-Months

The Visual Analog Scale (VAS) is self-administered instrument assessing average pain intensity. Subjects rated their pain on a horizontal line, 10 cm in length, anchored by word descriptors on each end (no pain to worst imaginable pain). A higher score indicates a higher pain level. The values range from 0 (minimum) to 10 (maximum).

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验